T1	Participants 573 622	among 120 patients with metastatic uveal melanoma
T2	Participants 702 742	One hundred one patients were randomized
T3	Participants 1123 1134	19 patients
T4	Participants 1155 1165	18 treated
T5	Participants 1640 1675	patients randomized to chemotherapy
T6	Participants 1805 1830	randomized to selumetinib
T7	Participants 2235 2265	Forty-nine percent of patients
T8	Participants 2441 2449	patients
T9	Participants 2587 2595	patients
